Physician profile
Antonino Mannone
NPI 1821073388
$4,443.61
in general payments reported to CMS, 2019-2025
30 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $174 · 2022: $221 · 2023: $1,127 · 2024: $1,333 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,583 · Education: $31.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,582.98 |
| Education | $31.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,849.53 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $692.17 | 2019-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $238.06 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.82 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $147.69 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $137.53 | 2024-2025 | Zenpep |
| Genzyme Corporation | $119.72 | 2023-2025 | |
| Ardelyx, INC. | $101.02 | 2023 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $95.34 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $94.01 | 2023-2024 | Dupixent |
| Celgene Corporation | $87.42 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $79.00 | 2019-2024 | Clenpiq |
| Janssen Biotech, INC. | $75.63 | 2019-2023 | Stelara |
| Lilly USA, LLC | $60.13 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $59.54 | 2019-2024 | Suflave |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.83 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.26 | 2023 | Cyltezo |
| Ethicon US, LLC | $52.42 | 2022 | |
| Amgen INC. | $38.13 | 2022-2023 | Avsola, Amjevita |
| Fresenius Kabi USA, LLC | $37.49 | 2023-2024 | Idacio |
| Celltrion USA INC. | $31.01 | 2024 | Zymfentra, Yuflyma |
| Pfizer INC. | $24.15 | 2024 | |
| Fujifilm Healthcare Americas Corporation | $23.67 | 2024 | Fujifilm |
| Ipsen Biopharmaceuticals, INC | $22.07 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $21.97 | 2025 | Rezdiffra |
| Sandoz INC. | $20.68 | 2024 | Hyrimoz |
| Exact Sciences Corporation | $19.68 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $18.49 | 2023 | |
| Concordia Pharmaceuticals INC. | $18.20 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonino Mannone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.